The British Association of Dermatologists guidelines for managing chronic urticaria provide evidence-based recommendations for treatment across primary, secondary, and tertiary care. The guidelines include practical clinical questions and updated patient information.
Chronic urticaria (CU) is a mast cell-driven disease characterized by the development of wheals, angioedema, or both for more than 6 weeks. The two major sub-types are chronic spontaneous urticaria (CSU) and inducible urticaria.
Novartis announced new baseline results from a real world study of 3,733 chronic urticaria (CU) patients showing many are not...
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline provides comprehensive recommendations for the definition, classification, diagnosis, and management of urticaria. This guideline is based on evidence and consensus from experts across multiple organizations.
A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic...
Chronic hand and foot eczema (CHFE) is a common inflammatory disorder that generally lasts for over 3 months.
Objective: To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1 antihistamine refractory CSU in Germany.
The EAACI Biologicals Guidelines for the treatment of chronic spontaneous urticaria (CSU) with omalizumab provide a comprehensive approach to managing this condition. The guidelines address practical issues such as responder selection, treatment duration, and cost-effectiveness.
The effectiveness of corticosteroids in antihistamine-resistant chronic urticaria (CU) is widely accepted although large studies on their use in this disease are lacking.
Chronic hand/foot eczemas are common, but treatment is often challenging, with widespread dissatisfaction over current available options. Detailed history is important, particularly with regard to potential exposure to irritants and allergens.